Merck pipeline update: ESA development ditched because of regulatory hurdles
This article was originally published in Scrip
Merck & Co has discontinued the development of its erythropoiesis-stimulating agent (ESA) MK-2578, for the treatment of anaemia, citing delays caused by the new regulatory restrictions the US FDA has enforced to address the cardiovascular risks associated with the drug class as the reason.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.